## The Food and Drug Administration's Approach to Evaluating Nicotine Replacement Therapies Part 15 Public Hearing

January 26, 2018 FDA White Oak Campus 10903 New Hampshire Ave. Bldg 31, Rm 1503A

| Food and Drug Administration                          |
|---|
| Epstein Becker & Green, P.C.                          |
|   |
| NJOY  |
|   |
| GlaxoSmithKline plc.                                  |
|   |
|   |
| Reynolds American Incorporated (RAI) Services Company |
|   |
| Intratab Labs Inc.                                    |
|   |
| Campaign for Tobacco Free Kids                        |
|   |
| Consumer Healthcare Products Association              |
|   |
| Consumer Choice Center                                |
|   |

| 12:00 – 12:05 pm Questions from the Panel   |  |
|---|--|
| 12:05 – 1:05 LUNCH BREAK  |  |
| 1:05 – 1:20 pm<br>Erika Sward   | American Lung Association                      |
| 1:20 - 1:25 pm Questions from the Panel   |  |
| 1:25 – 1:40 pm<br>Dr. Mark Watt   | Johnson & Johnson EAME Ltd                     |
| 1:40 - 1:45 pm Questions from the Panel   |  |
| 1:45 – 2:00 pm<br>Dr. Dorothy Hatsukami   | University of Minnesota                        |
| 2:00 - 2:05 pm Questions from the Panel   |  |
| 2:05 – 2:20 pm<br>Dr. Saul Shiffman   | Pinney Associates and University of Pittsburgh |
| 2:20 – 2:25 pm Questions from the Panel   |  |
| 2:25 – 2:40 pm<br>Chaim (Ben) Levilev   | Harmless Products Co.                          |
| 2:40 – 2:45 pm Questions from the Panel   |  |
| 2:45 – 3:45 pm OPEN PUBLIC HEARING  |  |
| 3:45 – 3:55 pm Concluding remarks<br>Dr. Rachel Sherman<br>Presiding Officer<br>Principal Deputy Commissioner | Food and Drug Administration                   |